<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.115343</article-id><article-id pub-id-type="publisher-id">ACM-42752</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210500000_21330134.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  小肠腺癌的研究进展
  Research Progress and Therapeutic Trend of Small Intestinal Neuroendocrine Neoplasms
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>思思</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>万</surname><given-names>苹</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>昆明理工大学附属医院消化科，云南 昆明</addr-line></aff><aff id="aff2"><addr-line>昆明理工大学医学院，云南 昆明</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>05</month><year>2021</year></pub-date><volume>11</volume><issue>05</issue><fpage>2387</fpage><lpage>2391</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  小肠腺癌是一种十分罕见的肿瘤，确诊往往即已发生转移，不能完全手术切除。如今肿瘤研究已经进入精准医疗的范畴，如何采用多学科方法，结合不同的治疗方案有效治疗小肠腺癌仍是目前的疑难问题。本篇综述尝试通过对以往的研究进行总结和更新的概述，以探寻未来的研究方向。
   In recent years, the incidence of small bowel adenocarcinoma (SBA) is group of rare tumors. The tumors often diagnosed with metastases and cannot be completely removed. Nowadays, tumor investigations have entered the category of precision medicine. How to treat SBA effectively with multidisciplinary approach and different treatment schemes is still a difficult problem at present. This review attempts to summarize and update previous studies to explore future research directions of SBA.
 
</p></abstract><kwd-group><kwd>小肠腺癌，小肠，治疗, Small Bowel Adenocarcinoma</kwd><kwd> Small Intestine</kwd><kwd> Treatment</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>小肠腺癌是一种十分罕见的肿瘤，确诊往往即已发生转移，不能完全手术切除。如今肿瘤研究已经进入精准医疗的范畴，如何采用多学科方法，结合不同的治疗方案有效治疗小肠腺癌仍是目前的疑难问题。本篇综述尝试通过对以往的研究进行总结和更新的概述，以探寻未来的研究方向。</p></sec><sec id="s2"><title>关键词</title><p>小肠腺癌，小肠，治疗</p></sec><sec id="s3"><title>Research Progress and Therapeutic Trend of Small Intestinal Neuroendocrine Neoplasms</title><p>Sisi Li<sup>1</sup>, Ping Wan<sup>2*</sup></p><p><sup>1</sup>Medical School of Kunming University of Science and Technology, Kunming Yunnan</p><p><sup>2</sup>Department of Gastroenterology, Affiliated Hospital of Kunming University of Science and Technology, Kunming Yunnan</p><p><img src="//html.hanspub.org/file/52-1572252x4_hanspub.png" /></p><p>Received: Apr. 25<sup>th</sup>, 2021; accepted: May 8<sup>th</sup>, 2021; published: May 28<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/52-1572252x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>In recent years, the incidence of small bowel adenocarcinoma (SBA) is group of rare tumors. The tumors often diagnosed with metastases and cannot be completely removed. Nowadays, tumor investigations have entered the category of precision medicine. How to treat SBA effectively with multidisciplinary approach and different treatment schemes is still a difficult problem at present. This review attempts to summarize and update previous studies to explore future research directions of SBA.</p><p>Keywords:Small Bowel Adenocarcinoma, Small Intestine, Treatment</p><disp-formula id="hanspub.42752-formula53"><graphic xlink:href="//html.hanspub.org/file/52-1572252x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/52-1572252x8_hanspub.png" /> <img src="//html.hanspub.org/file/52-1572252x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 小肠腺癌背景介绍</title><p>小肠是一个可以高度增殖上皮的器官，胃肠道中小肠长度占75%，大约5%的胃肠道恶性肿瘤是由小肠引起的 [<xref ref-type="bibr" rid="hanspub.42752-ref1">1</xref>]。小肠癌主要包括SBA、神经内分泌肿瘤，这两类小肠癌发病率较高，其实是胃肠道间质瘤，肉瘤和淋巴瘤等。结肠腺癌在消化道肿瘤发生病变中占主导地位，占总发病率的98%以上，而小肠腺癌(Small Bowel Adenocarcinoma, SBA)占30%~40% [<xref ref-type="bibr" rid="hanspub.42752-ref2">2</xref>]。小肠引起的原发性肿瘤既可以是良性也可是恶性，SBA的预后往往较差，晚期SBA的预后比结直肠癌的预后差，但相比胃或胰腺肿瘤预后好 [<xref ref-type="bibr" rid="hanspub.42752-ref3">3</xref>]。十二指肠发生腺癌的占比率最大，其次为空肠、回肠 [<xref ref-type="bibr" rid="hanspub.42752-ref4">4</xref>]。由于小肠生理结构具有特殊性，同时它占比消化道中重要且很大的部分，常规检查中往往存在内镜或结肠镜无法触及的区域。再者，其SBA发病特多为非典型早期症状。这一系列的原因致使其早期诊断困难以及存在误诊率较高，所以至今其仍缺乏标准的治疗方案和手段。</p><p>SBA的风险因素主要包含以下几方面：</p><p>1) 生活方式</p><p>据报道 [<xref ref-type="bibr" rid="hanspub.42752-ref5">5</xref>]，吸烟和食用一些食物，如红肉、糖和淀粉类的食物会增加患SBA的风险。一项来自亚洲多个国家的研究的数据 [<xref ref-type="bibr" rid="hanspub.42752-ref6">6</xref>]，平均随访近11年，超过500,000名受试者，计算了身体质量指数和吸烟和饮酒的危险比(HRs)结果表明体重指数升高和高饮酒与SBA风险增加的趋势无显着相关性，该分析并未将吸烟识别为危险因素。</p><p>2) 家族性腺瘤性息肉病</p><p>家族性腺瘤性息肉病(Familial Adenomatous Polyposis, FAP)是APC基因常染色体显性突变的结果，在FAP患者中，SBA是除结直肠癌的第二常见原发癌，十二指肠腺瘤出现在80%的病例中，并在4%的病例中发展为腺癌 [<xref ref-type="bibr" rid="hanspub.42752-ref7">7</xref>]。Dabaja BS等人的一项回顾性研究， [<xref ref-type="bibr" rid="hanspub.42752-ref8">8</xref>] 分析了217例SBA患者的病因和预后以及治疗方式等方面，结果显示中位生存期为20个月，5年总生存率为26%。因此一旦确诊SBA，建议患者进行定期的检查，有助于改善预后。</p><p>3) 炎症性肠病</p><p>炎症性肠病是一种慢性肠病，其发病机制中的病因包括遗传易感性，环境，微生物因素及其与肠上皮细胞的相互作用以及先天性和适应性免疫系统的组成部分。包括克罗恩病和溃疡性结肠炎，通常为慢性透壁炎症，随着疾病进展长时间的演化可能促使发生癌变。克罗恩病的特征在于小肠的透壁肉芽肿性炎症以不连续的方式，并且倾向于形成狭窄，狭窄和瘘管。与克罗恩氏病相关的癌症通常是回肠腺癌，一些基于人群的研究估计，克罗恩病患者的小肠癌的相对风险为33.2 [<xref ref-type="bibr" rid="hanspub.42752-ref9">9</xref>]。患克罗恩病10年后，累积风险约为0.2%，但25年约2.2% [<xref ref-type="bibr" rid="hanspub.42752-ref10">10</xref>]。</p><p>4) Peutz-Jeghers综合征</p><p>LKB1/STK11肿瘤抑制基因中的种系突变会引起Peutz-Jeghers综合征(Peutz-Jeghers syndrome, PJS)。 [<xref ref-type="bibr" rid="hanspub.42752-ref11">11</xref>]。PJS是常染色体显性疾病，大多数患者位于19p13.3区域的STK11基因存在致病突变，特征是粘膜上有黑色素斑点，易形成多个胃肠道错构瘤和息肉散布在整个小肠中 [<xref ref-type="bibr" rid="hanspub.42752-ref12">12</xref>]。并且PJS患者的发生于小肠的癌症相对风险为极高，为520，95%置信度为[220, 1306] [<xref ref-type="bibr" rid="hanspub.42752-ref13">13</xref>]。</p><p>5) 林奇综合症</p><p>林奇综合症也是一种常染色体显性遗传病，也叫做遗传性非息肉性结直肠癌，由DNA错配修复基因MMR突变引起的。突变携带者估计发展为小肠癌的终生风险约为4%，与普通人群相比，相对风险超过100 [<xref ref-type="bibr" rid="hanspub.42752-ref14">14</xref>]。它可以通过MMR免疫组化和微卫星不稳定性(Microsatellite Instability, MSI)的PCR检测来进行诊断，MSI是这种肿瘤的遗传表型。</p><p>因此对于SBA来讲，确诊患有具有可能发展为小肠癌疾病的患者以及有家族遗传史的患者需要定期检查，患者包括普通人在饮食上也应多样化，不应挑食只吃单一性的食物种类。</p></sec><sec id="s6"><title>2. 小肠腺癌的检查手段</title><p>在内镜方面，许多研究都报告了双气囊内镜(Double-ballon Endoscopy, DBE)检查对小肠癌患者进行检查的有效性和安全性 [<xref ref-type="bibr" rid="hanspub.42752-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.42752-ref16">16</xref>]。Li Tang等人的研究中 [<xref ref-type="bibr" rid="hanspub.42752-ref17">17</xref>]，共有2806例患者接受了DBE检查，检出病灶1696例，检出率为60.4%，对于接受内镜治疗的小肠息肉患者，没有发生消化道出血和穿孔等并发症。但其技术耗时，并且经口或者经肛很难贯穿通过整个消化道，具有会很大挑战性，通常需要患者保持深度镇静或全身麻醉的状态，因此患者检查具有一定的负担。</p><p>胶囊内镜(Capsule Endoscopy, CE)对小肠疾病的检出率很高。Ming Ren等人 [<xref ref-type="bibr" rid="hanspub.42752-ref18">18</xref>] 检查155例患者，整个小肠的检查完成了93.1%，对不明原因的胃肠道出血的诊断率为89.7%，腹痛的诊断率为73.8%。CE采取非侵入性进入人体的方式包括肿瘤和炎性病变均具有较高的诊断价值。鉴于胶囊内镜检查的简便性，安全性和可靠性，它是诊断小肠疾病的重要检查工具 [<xref ref-type="bibr" rid="hanspub.42752-ref19">19</xref>]。但CE存在胶囊滞留的隐患，因此使用CE检查前要明确病人的病史，如先前有无进行过腹部手术、曾服用的处方药物和是否有梗阻症状等等，同时也要注意的是CE无法评估这些肿瘤的壁和壁外范围，因此CE的使用具有一定的局限性。</p><p>小肠CT造影(Computed Tomography Enterography, CTE)是一种十分卓越的非侵入性成像方式，CTE通过显示肠壁高强化、分层和增厚来描绘小肠图像，CTE尤其对炎症性肠病的患者的检查更具有优势 [<xref ref-type="bibr" rid="hanspub.42752-ref20">20</xref>]。石爱军等人的研究中 [<xref ref-type="bibr" rid="hanspub.42752-ref21">21</xref>]，将CE与CTE联合，对133例疑似小肠疾病患者，分成实验组与两组对照组A、B，对照组为A组，只使用CE进行检查；对照组B组只使用CTE进行检查;实验组同时使用CE和CTE，结果发现实验组的病变病因诊断和检出率明显优于对照组A，且P &lt; 0.05，说明两者联合诊断的临床价值更高。</p><p>磁共振成像(Magnetic Resonance Imaging, MRI)与计算机体层摄影(computed tomography, CT)是影像学用来诊断疾病的常用方法，MRI相比CT具有提供动态信息的优势，突出内壁和壁外肠道细节，并提供了血管和功能信息，有助于诊断低度狭窄和确定阻塞的程度 [<xref ref-type="bibr" rid="hanspub.42752-ref22">22</xref>]。</p></sec><sec id="s7"><title>3. 小肠腺癌的治疗</title><p>很少有研究报道针对SBA的优化管理以及治疗，一般的做法是采用以治疗结直肠癌的方式进行对SBA的治疗管理。目前，原发肿瘤的手术完全切除是局部疾病的唯一可能的治疗方法。用于治疗局部SBA的切除类型取决于原发肿瘤的位置。对于空肠或回肠肿瘤，部分切除术是首选的切除方法，同时取回5~9个淋巴结进行评估，有助于改善预后 [<xref ref-type="bibr" rid="hanspub.42752-ref23">23</xref>]。</p><p>转移性或局部不可切除的SBA的预后较差，Xiaoyuan Li等人的研究 [<xref ref-type="bibr" rid="hanspub.42752-ref24">24</xref>] 表明：34例入组患者均接受FOLFOX/XELOX (n = 27)，FOLFIRI/CAPIRI (n = 5)，GEMOX (n = 1)和TP (n = 1)其中的一组方案作为一线治疗方案：缓解率以及疾病控制率分别为11.8%和61.8%，中位无进展生存期(PFS)和总体生存期(OS)分别为4.5和13.8个月，且多变量分析肝转移与不良的PFS独立相关，说明全身化疗的联合疗法结合局部治疗原发性肿瘤和少发转移可能会改善部分患者的预后。其他的化疗药物包括伊马替尼、舒尼替尼、瑞戈非尼，没有前瞻性随机数据可确定哪种化疗方案最有效。</p><p>Koen P. Rovers等人于近年发表了一项回顾性研究 [<xref ref-type="bibr" rid="hanspub.42752-ref25">25</xref>]，腹膜转移(PM)影响着约三分之一的转移性SBA患者，对于这种转移SBA的治疗选择包括：全身治疗 &#177; 姑息性手术以及腹膜内化疗 + 细胞减灭术(CRS + IPC)，研究全身治疗的18项研究和研究CRS + IPC的6项观察性研究：在研究全身疗法的研究中，客观缓解率(ORR)，疾病控制率(DCR)，中位PFS，中位总生存期(Overall survival, OS)和III-V级毒性范围为6%至50%，50%至90%，3至11个月，8至20个月和10%分别达到68%，并且与氟嘧啶-伊立替康，氟嘧啶–顺铂等方案相比，氟嘧啶–奥沙利铂显示出有利的生存结果，氟嘧啶–奥沙利铂被视为最佳的一线全身治疗手段，而CRS + IPC可能比全身治疗更有效且安全，中位无病生存期(Disease-free survival, DFS)，中位OS和III-V级发病率分别为10到12个月，16到47个月和12%到35%。这项研究对于转移性SBA患者具有一定的参考意义。</p><p>对于微卫星高度不稳定(MSI-H)或错配修复功能缺陷(Different Mismatch Repair, dMMR)的肿瘤，在二线治疗中单独使用PD-1抑制剂免疫检查点抑制剂疗法 [<xref ref-type="bibr" rid="hanspub.42752-ref26">26</xref>]。nab-紫杉醇化疗法可作为对免疫检查点抑制剂治疗无效肿瘤的第二选择 [<xref ref-type="bibr" rid="hanspub.42752-ref27">27</xref>]。</p><p>迄今为止，与结直肠癌相比，很少数据显示关于SBA的特定生物疗法或靶向药物治疗。未来对于SBA的治疗可能会在研究大通量分子测序以及其研究分子机制的基础上不断发展新型靶向药物与生物免疫疗法。</p></sec><sec id="s8"><title>4. 总结</title><p>SBA是一种罕见的恶性肿瘤，近几十年来呈上升趋势。与结直肠癌相比，SBA更常发现于晚期诊断。SBA风险增加与遗传和家族性疾病与有关。尽管SBA的总体发生率较低，但由于非特异性症状且通常会延迟诊断，因此预后较差。对于局部发生的SBA，小肠部分切除术是治疗的主要手段。转移性SBA很少可以通过原发肿瘤切除和转移切除术来治愈，大多数患有转移性SBA的患者均接受全身治疗。一般根据肿瘤的位置和患者的病史，建议对所有SBA患者进行MMR或MSI测试，这有助于识别林奇综合征患者。此外，SBA的独特遗传特征已成为研究的主题，这可能会为SBA带来更多的新的靶向或免疫疗法治疗选择。</p></sec><sec id="s9"><title>文章引用</title><p>李思思,万 苹. 小肠腺癌的研究进展Research Progress and Therapeutic Trend of Small Intestinal Neuroendocrine Neoplasms[J]. 临床医学进展, 2021, 11(05): 2387-2391. https://doi.org/10.12677/ACM.2021.115343</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.42752-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Siegel, R.L., Miller, K.D. and Jemal, A. (2016) Cancer Statistics, 2016. CA: A Cancer Journal for Clinicians, 66, 7-30.  
&lt;br&gt;https://doi.org/10.3322/caac.21332</mixed-citation></ref><ref id="hanspub.42752-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Schottenfeld, D., Beebe-Dimmer, J.L. and Vigneau, F.D. (2009) The Epidemiology and Pathogenesis of Neoplasia in the Small Intestine. Annals of Epidemiology, 19, 58-69. &lt;br&gt;https://doi.org/10.1016/j.annepidem.2008.10.004</mixed-citation></ref><ref id="hanspub.42752-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Aparicio, T., Zaanan, A., Svrcek, M., et al. (2014) Small Bowel Adenocarcinoma: Epidemiology, Risk Factors, Diagnosis and Treatment. Digestive and Liver Disease, 46, 97-104. &lt;br&gt;https://doi.org/10.1016/j.dld.2013.04.013</mixed-citation></ref><ref id="hanspub.42752-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Agrawal, S., McCarron, E.C., Gibbs, J.F., et al. (2007) Surgical Management and Outcome in Primary Adenocarcinoma of the Small Bowel. Annals of Surgical Oncology, 14, 2263-2269. &lt;br&gt;https://doi.org/10.1245/s10434-007-9428-2</mixed-citation></ref><ref id="hanspub.42752-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Bennett, C.M., Coleman, H.G., Veal, P.G., et al. (2015) Lifestyle Factors and Small Intestine Adenocarcinoma Risk: A Systematic Review and Meta-Analysis. Cancer Epidemiology, 39, 265-273.  
&lt;br&gt;https://doi.org/10.1016/j.canep.2015.02.001</mixed-citation></ref><ref id="hanspub.42752-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Boffetta, P., Hazelton, W.D., Chen, Y., et al. (2012) Body Mass, Tobacco Smoking, Alcohol Drinking and Risk of Cancer of the Small Intestine—A Pooled Analysis of over 500,000 Subjects in the Asia Cohort Consortium. Annals of Oncology, 23, 1894-1898. &lt;br&gt;https://doi.org/10.1093/annonc/mdr562</mixed-citation></ref><ref id="hanspub.42752-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Vasen, H.F., Bülow, S., Myrhøj, T., et al. (1997) Decision Analysis in the Management of Duodenal Adenomatosis in Familial Adenomatous Polyposis. Gut, 40, 716-719. &lt;br&gt;https://doi.org/10.1136/gut.40.6.716</mixed-citation></ref><ref id="hanspub.42752-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Dabaja, B.S., Suki, D., Pro, B., et al. (2004) Adenocarcinoma of the Small Bowel: Presentation, Prognostic Factors, and Outcome of 217 Patients. Cancer, 101, 518-526. &lt;br&gt;https://doi.org/10.1002/cncr.20404</mixed-citation></ref><ref id="hanspub.42752-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Canavan, C., Abrams, K.R. and Mayberry, J. (2006) Meta-Analysis: Colorectal and Small Bowel Cancer Risk in Patients with Crohn’s Disease. Alimentary Pharmacology &amp; Therapeutics, 23, 1097-1104.  
&lt;br&gt;https://doi.org/10.1111/j.1365-2036.2006.02854.x</mixed-citation></ref><ref id="hanspub.42752-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Palascak-Juif, V., Bouvier, A.M., Cosnes, J., et al. (2005) Small Bowel Adenocarcinoma in Patients with Crohn’s Disease Compared with Small Bowel Adenocarcinoma de Novo. Inflammatory Bowel Diseases, 11, 828-832.  
&lt;br&gt;https://doi.org/10.1097/01.mib.0000179211.03650.b6</mixed-citation></ref><ref id="hanspub.42752-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Lim, W., Hearle, N., Shah, B., et al. (2003) Further Observations on LKB1/STK11 Status and Cancer Risk in Peutz- Jeghers Syndrome. British Journal of Cancer, 89, 308-313. &lt;br&gt;https://doi.org/10.1038/sj.bjc.6601030</mixed-citation></ref><ref id="hanspub.42752-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Beggs, A.D., Latchford, A.R., Vasen, H.F., et al. (2010) Peutz-Jeghers Syndrome: A Systematic Review and Recommendations for Management. Gut, 59, 975-986. &lt;br&gt;https://doi.org/10.1136/gut.2009.198499</mixed-citation></ref><ref id="hanspub.42752-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Giardiello, F.M., Brensinger, J.D., Tersmette, A.C., et al. (2000) Very High Risk of Cancer in Familial Peutz-Jeghers Syndrome. Gastroenterology, 119, 1447-1453. &lt;br&gt;https://doi.org/10.1053/gast.2000.20228</mixed-citation></ref><ref id="hanspub.42752-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Koornstra, J.J., Kleibeuker, J.H. and Vasen, H.F. (2008) Small-Bowel Cancer in Lynch Syndrome: Is It Time for Surveillance? The Lancet Oncology, 9, 901-905. &lt;br&gt;https://doi.org/10.1016/S1470-2045(08)70232-8</mixed-citation></ref><ref id="hanspub.42752-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Cazzato, I.A., Cammarota, G., Nista, E.C., et al. (2007) Diagnostic and Therapeutic Impact of Double-Balloon Enteroscopy (DBE) in a Series of 100 Patients with Suspected Small Bowel Diseases. Digestive and Liver Disease, 39, 483-487. &lt;br&gt;https://doi.org/10.1016/j.dld.2007.01.019</mixed-citation></ref><ref id="hanspub.42752-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Chen, W.G., Shan, G.D., Zhang, H., et al. (2016) Double-Balloon Enteroscopy in Small Bowel Diseases: Eight Years Single-Center Experience in China. Medicine (Baltimore), 95, e5104. &lt;br&gt;https://doi.org/10.1097/MD.0000000000005104</mixed-citation></ref><ref id="hanspub.42752-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Paski, S.C. and Semrad, C.E. (2009) Small Bowel Tumors. Gastrointestinal Endoscopy Clinics of North America, 19, 461-479. &lt;br&gt;https://doi.org/10.1016/j.giec.2009.04.012</mixed-citation></ref><ref id="hanspub.42752-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Ren, M., Yuan, G., Zhu, S.L., et al. (2009) Evaluation of Capsule Endoscopy in the Diagnosis of Small Bowel Disease. Chinese Journal of Gastrointestinal Surgery, 12, 163-166.</mixed-citation></ref><ref id="hanspub.42752-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Li, X., Gui, Y., Shen, F., et al. (2018) The Application Value of Capsule Endoscopy in Diagnosing Small Intestinal Carcinoma. Journal of Cancer Research and Therapeutics, 14, 57-60. &lt;br&gt;https://doi.org/10.4103/jcrt.JCRT_584_17</mixed-citation></ref><ref id="hanspub.42752-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Paulsen, S.R., Huprich, J.E., Fletcher, J.G., et al. (2006) CT Enterography as a Diagnostic Tool in Evaluating Small Bowel Disorders: Review of Clinical Experience with over 700 Cases. RadioGraphics, 26, 641-657.  
&lt;br&gt;https://doi.org/10.1148/rg.263055162</mixed-citation></ref><ref id="hanspub.42752-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">石爱军, 包忠英. 胶囊内镜联合小肠CT造影在小肠疾病中的诊断价值[J]. 影像研究与医学应用, 2017, 1(4): 82-84.</mixed-citation></ref><ref id="hanspub.42752-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Kamaoui, I., De-Luca, V., Ficarelli, S., et al. (2010) Value of CT Enteroclysis in Suspected Small-Bowel Carcinoid Tumors. American Journal of Roentgenology, 194, 629-633. &lt;br&gt;https://doi.org/10.2214/AJR.09.2760</mixed-citation></ref><ref id="hanspub.42752-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Tran, T.B., Qadan, M., Dua, M.M., et al. (2015) Prognostic Relevance of Lymph Node Ratio and Total Lymph Node Count for Small Bowel Adenocarcinoma. Surgery, 158, 486-493. &lt;br&gt;https://doi.org/10.1016/j.surg.2015.03.048</mixed-citation></ref><ref id="hanspub.42752-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Li, X., Ying, H., Cheng, Y., et al. (2019) Clinicopathological Features and Treatment Outcomes of Metastatic or Locally Unresectable Small Bowel Adenocarcinoma. Journal of B.U.ON., 24, 2539-2545.</mixed-citation></ref><ref id="hanspub.42752-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Rovers, K.P., de Bree, E., Yonemura, Y., et al. (2017) Treatment of Peritoneal Metastases from Small Bowel Adenocarcinoma. International Journal of Hyperthermia, 33, 571-578. &lt;br&gt;https://doi.org/10.1080/02656736.2016.1266700</mixed-citation></ref><ref id="hanspub.42752-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Giuffrida, P., Arpa, G., Grillo, F., et al. (2020) PD-L1 in Small Bowel Adenocarcinoma Is Associated with Etiology and Tumor-Infiltrating Lymphocytes, in Addition to Microsatellite Instability. Modern Pathology, 33, 1398-1409.  
&lt;br&gt;https://doi.org/10.1038/s41379-020-0497-0</mixed-citation></ref><ref id="hanspub.42752-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Overman, M.J., Adam, L., Raghav, K., et al. (2018) Phase II Study of Nab-Paclitaxel Inrefractory Small Bowel Adenocarcinoma and CpG Island Methylatorphenotype (CIMP)-High Colorectal Cancer. Annals of Oncology, 29, 139-144.  
&lt;br&gt;https://doi.org/10.1093/annonc/mdx688</mixed-citation></ref></ref-list></back></article>